WASHINGTON: AstraZeneca pharmaceutical company will submit a request for approval of its novel Coronavirus vaccine in the US later this year, the company said in a statement.
Earlier this year, concerns arose on the side effects of the AstraZeneca vaccine because of blood clotting cases that were very rare after vaccination.
After several countries temporarily suspend the use of vaccines, which said it considered the benefits of the drug to exceed the risks.
“We continue to work with the FDA [US Food and Drug Administration] on subject,” said the company on Wednesday.
“At present, the situation in connection with the pandemic and availability of alternative vaccine supplies in the US does not really support the approval of emergency use.
So, we believe that US agreement will go through BLA [biology license application] which we expected to be submitted later this year.” FDA so far It has three official vaccines for emergencies used throughout the United States, in February 2021, the World Health Organization registered two versions of Astrazeneca / Oxford Covid-19 vaccines for emergency use, giving green lights for this vaccine to roll out globally through the Covax mechanism.
According to AstraZeneca, the vaccine shows efficiency of 92 percent and 86 percent of their respective hospitalization in the case of Delta and Alfa variants.
At the same time, an English-based study from May, published in the New England Journal of Medicine on July 21, shows that Astrazeneca 33% effective after one dose, 60% effective after two.